These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37634938)

  • 1. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
    Doggrell SA
    Expert Opin Drug Deliv; 2023; 20(9):1189-1199. PubMed ID: 37634938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
    Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
    Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
    Hauser RA; Zeitlin L; Fisher S; D'Souza R
    J Parkinsons Dis; 2020; 10(3):915-925. PubMed ID: 32568108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
    J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
    Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Levodopa Formulations for Parkinson's Disease.
    Freitas ME; Ruiz-Lopez M; Fox SH
    CNS Drugs; 2016 Nov; 30(11):1079-1095. PubMed ID: 27743318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
    Rosebraugh M; Liu W; Neenan M; Facheris MF
    J Parkinsons Dis; 2021; 11(4):1695-1702. PubMed ID: 34366380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
    J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program.
    LeWitt PA; Stocchi F; Arkadir D; Caraco Y; Adar L; Perlstein I; Case R; Giladi N
    Front Neurol; 2022; 13():1036068. PubMed ID: 36438968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction].
    Szász JA; Szatmári S; Constantin V; Mihály I; Török Á; Frigy A; Metz J; Kelemen K; Szász RM; Forró T; Baróti B; Orbán-Kis K
    Orv Hetil; 2022 Jul; 163(30):1189-1195. PubMed ID: 35895443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.